Showing 4801-4810 of 5957 results for "".
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- National Optometric Association to Host Regional Meeting at Vision Expo East 2021https://modernod.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announce that the National Optometric Association (NOA), an organization dedicated to advancing the visual health of minority populations through the delivery of effective and efficient eye and vision ca
- Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolioshttps://modernod.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.1 These next-generation IOLs
- Computer Model Fosters Potential Improvements to ‘Bionic Eye’ Technologyhttps://modernod.com/news/computer-model-fosters-potential-improvements-to-bionic-eye-technology/2479063/There are millions of people who face the loss of their eyesight from degenerative eye diseases. The genetic disorder retinitis pigmentosa alone affects 1 in 4,000 people worldwide. Today, there is technology available to offer partial eyesight to people with that syndrome. The Argus II, the worl
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- Systematic Review of Standalone iStent Trabecular Micro-Bypass Glaucoma Surgeryhttps://modernod.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/A new meta-analysis of the iStent and iStent inject (Glaukos) found that standalone trabecular micro-bypass glaucoma surgery with the devices is associated with clinically relevant reductions in intraocular pressure. The focus of the study, which was published in the Journal of Glaucom
- OneSight Partners With Anthem Blue Cross and Blue Shield Foundation to Provide Free Eye Exams and Glasses in Cincinnatihttps://modernod.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/Preventative care visits have dropped significantly over the course of the pandemic, and this is especially true in under-served communities. That’s why the Anthem Blue Cross and Blue Shield Foundation teamed up with OneSight, a leading global vision care nonprofit, to provide free eye exams and
- Infectious Disease Researcher Appointed Inaugural Chief Scientific Officer at Mass Eye and Earhttps://modernod.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/Michael S. Gilmore, PhD, a microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear. Dr. Gilmore will assume the role on May 1, 2021. He has served as Director of the Infectious Disease
- COVID-19 Accelerates Trend of Hospitals Acquiring Ambulatory Surgery Centershttps://modernod.com/news/covid-19-accelerates-trend-of-hospitals-acquiring-ambulatory-surgery-centers/2479048/The pandemic has accelerated a growing desire among providers and even some medical technology manufacturers to acquire or get into the surgery center business, experts say, according to a Fierce Healthcare
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt